Q-omics provides the consensus-scored MYCBP profile across patient tissues and cancer cell-line models. MYCBP expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MYCBP is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, MYCBP RNA expression shows 19,376 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, KIRC, and ACC as cancer lineages where MYCBP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYCBP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYCBP survival associations across molecular data types. MYCBP RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYCBP RNA expression–survival associations across cancer types. High MYCBP expression shows unfavorable associations in KICH, LIHC, CESC, PAAD and LGG, but favorable associations in UCEC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for MYCBP RNA expression.
This table summarizes MYCBP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MYCBP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYCBP shows lower tumor expression in KIRC, KICH and THCA and higher tumor expression in BLCA, LIHC and STAD. The KIRC box plot shows higher MYCBP RNA expression in normal versus tumor tissue (log2 FC = −0.682, t-test p < 0.001).
This table shows molecular features associated with MYCBP in patient tissues and cancer cell lines. In patient samples, MYCBP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MYCBP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
